Biology Reference
In-Depth Information
Sieg S, Yildirim Z, Smith D, Kayagaki N, Yagita H, Huang Y, Kaplan D. 1996. Herpes simplex
virus type 2 inhibition of Fas ligand expression. J Virol 70: 8747±8751.
Sieg S, Smith D, Yildirim Z, Kaplan D. 1997. Fas ligand de®ciency in HIV disease. Proc Natl Acad
Sci USA 94: 5860±5865.
Smith D, Sieg S, Kaplan D. 1998. Aberrant detection of cell surface Fas ligand with anti-peptide
antibodies. J Immunol 160: 4159±4160.
Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa
S, Ohga S, Hatake K, Drummond AH, Nagata S. 1996. Fas ligand in human serum. Nat Med 2:
317±322.
Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J. 2000. Human immunode®ciency
virus-speci®c circulating CD8 T lymphocytes have down-modulated CD3z and CD28, key sig-
naling molecules for T-cell activation. J Virol 74: 7320±7330.
van Gijlswijk RP, Zijlmans HJ, Wiegant J, Bobrow MN, Erickson TJ, Adler KE, Tanke HJ, Raap
AK. 1997. Fluorochrome-labeled tyramides: use in immunocytochemistry and ¯uorescence in
situ hybridization. J Histochem Cytochem 45: 375±382.
Wang Z, Morris GF, Reed JC, Kelly GD, Morris CB. 1999. Activation of Bcl-2 promoter-directed
gene expression by the human immunode®ciency virus type-1 Tat protein. Virol 10: 502±510.
Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. 1997. Human CD4
cells transfected
with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med 3:
659±664.
Zola H, Neoh SH, Mantizioris BX, Webster J, Loughnan MS. 1990. Detection by immuno-
¯uorescence of surface molecules present in low copy numbers. J Immunol Methods 135: 247±
255.
Zolla-Pazner S, O'Leary J, Burda S, Gorny MK, Kim M, Mascola J, McCutchan F. 1995. Sero-
typing of primary human immunode®ciency virus type 1 isolates from diverse geographic loca-
tions by ¯ow cytometry. J Virol 69: 3807±3815.
